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ABSTRACT
The increased risk of pneumonia from proton pump inhibitors (PPI) has been addressed in recent studies. This study aimed to investigate the risk of hospital-acquired pneumonia (HAP) in critically ill patients receiving PPI or sucralfate. This retrospective observational
cohort study analyzed patients who were prescribed with PPIs or sucralfate for stress ulcer prophylaxis in intensive care units (ICU). A
propensity score and other risk factors were used to calculate the adjusted odds ratio (OR) for the two groups. The final cohort comprised
388 patients with 302 patients on PPI and 86 patients on sucralfate therapies. HAP developed in 63 patients (20.86%) on PPI, and 8 patients
(9.30%) on sucralfate (adjusted OR 3.37, 95% CI 1.35-8.45, p-value 0.009). The enrolled patients on PPI therapy with an APACHE II
score > 13 (adjusted OR 3.70, 95% CI 1.04-13.10, p-value 0.043), or those on PPI therapy with an ICU stay of more than 8 days (adjusted
OR 9.04, 95% CI 1.94-42.06, p-value 0.005) had the highest risk of developing HAP. Patients in medical ICU treated with PPIs had a
higher risk of developing HAP than those treated with sucralfate. For the ICU patients requiring stress ulcer prophylaxis, sucralfate can be
considered as a priority treatment. The risk and benefit of PPI treatment should be evaluated for patients who may have a longer ICU stay
or have a high APACHE II score.
Key words: hospital-acquired pneumonia, pneumonia, proton pump inhibitor, sucralfate, stress ulcer prophylaxis, acid-suppressive pharmacologic agents

INTRODUCTION
Concerns for the risk for pneumonia limited the use of
proton pump inhibitor (PPI) for stress ulcer prevention(1).
Acid-suppressive pharmacologic agents, such as histamine-2
receptor antagonists (H2RAs) and PPIs, raise the gastric pH
and thus, promote the proliferation of gram-negative bacilli
in stomach. Retrograde colonization of the aerodigestive
tract and the micro-aspiration of gastric fluid into the upper
respiratory tract and lung have been shown to facilitate the
occurrence of pneumonia(2,3). Studies have demonstrated
that antacids and H2RAs, used for preventing stress ulcers,
may increase the risk of hospital-acquired pneumonia (HAP)
* Author for correspondence. Tel: +886-2-29307930 ext. 1110;
Fax: +886-2-86621163; E-mail: shawn@tmu.edu.tw

in critically ill patients(4-6). The use of PPIs linked to an
increased risk of community-acquired pneumonia (CAP) in
ambulatory settings was also noted in many studies(7-11).
Despite the controversial association between PPI and
pneumonia, an increased use of PPI in intensive care units
(ICU) has been observed in recent years(12). The American
Thoracic Society (ATS) has not endorsed the use of PPI in
preventing stress ulcers in ICU patients(13). However, PPI
was suggested as a treatment to prevent stress ulcers by the
newer international guidelines for management of severe
sepsis and septic shock in 2008 as the surviving sepsis
campaign(14). According to a report on a retrospective cohort
study performed by Beaulieu et al., no significant difference
in the risk of HAP was observed between ICU patients treated
with PPI and those who were not (Adjusted Hazard Ratio
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0.63, 95% CI 0.39-1.01)(15). However, conflicting results
were found in a cohort study in 2009, which reported an
increased risk of HAP with pantoprazole use when compared
with ranitidine for stress ulcer prophylaxis for patients more
than 18 years old in surgical ICUs (adjusted OR 2.7, 95%
CI 1.1-6.7, p-value 0.034)(16). Since the risk of bleeding in
critical care patients with respiratory failure or coagulopathy
is high, it is necessary to ensure appropriate treatment and
prophylaxis for stress ulcers(17).
Sucralfate, a cytoprotective agent, has been listed as
an acceptable prophylaxis for stress ulcer by practice guidelines, with a slightly higher rate of clinically signiﬁcant
gastric bleeding compared with H2 antagonists(13,18). It has
been showed with less impact on stomach acidity and associated with lower incidence of late onset pneumonia compared
to antacids and H2RAs(5). Randomized trials also suggested
a trend toward reduced ventilator-associated pneumonia
(VAP) with sucralfate(19). This study aimed to investigate the
association between HAP and the use of stress ulcer prophylaxis for patients in medical ICUs. To find the adequate stress
ulcer prophylaxis for patients with high risk of pneumonia,
sucralfate was selected as the comparator vis-à-vis PPI in
this study. The risk factors related to HAP were also analyzed
to identify the high risk groups for supporting the prevention
of stress ulcer.

MATERIALS AND METHODS
I. Study Design and Subjects
In this retrospective cohort study, patients were included
as those admitted into the ICU of Keelung Chang Gung
Memorial Hospital, a regional teaching hospital, during the
period of January 1, 2000 to December 31, 2009. The study
protocol was approved by the institutional review board
(IRB) of the hospital. All data were collected from the electronic medical records in the Healthcare Information System
of the hospital. Patients more than 18 years old, with an ICU
stay of more than 48 h and who received either PPI (omeprazole, pantoprazole, esomeprazole, lansoprazole) or sucralfate
were enrolled in the study. Patients who received a combined
therapy or switched therapy of PPIs, sucralfate, or H2RAs
were excluded. Other exclusion criteria were those who (1)
had a diagnosis of pneumonia during three months before
admission, (2) had documented aspiration before their ICU
admission, (3) had a history of dysphagia, or (4) had a history
of immunosuppression (defined as steroid treatment use more
than 6 months, receipt of chemotherapy within the previous
year, or treatment with any anti-rejection medications within
the previous year). For patients who had multiple hospital
admissions during the study period, only the first admission
was eligible for inclusion.
II. Outcome of Interest
HAP is defined as pneumonia that occurs 48 h or later

after ICU admission(20). The National Nosocomial Infection
Surveillance system algorithm was applied as the criteria of
pneumonia(13). The diagnosis of pneumonia can be confirmed
if the patient has at least two of the following clinical features:
(1) a new onset of fever, (2) leukocytosis or leucopenia, (3)
a new onset of purulent sputum, a change in the character
of the sputum, increased respiratory secretions, or increased
suctioning requirements, (4) a new onset of worsening cough,
dyspnea, tachypnea, or (5) a decline in oxygenation (by
PaO2/fraction of inspired oxygen [FIO2] < 40%), increased
oxygen requirements, or an increased ventilation demand. In
addition, confirmation of progressive infiltration, consolidation or cavitation must be evaluated in two or more serial
chest radiographic exams. Pneumonia that occurred after the
use of PPIs or sucralfate was documented as a single case.
The previous uses of PPIs and sucralfate before ICU admission in the same admission within the hospital were also
documented.
III. Statistical Analysis
The statistical analysis used the X2 test for categorical
variables and an independent t-test for continuous variables.
The differences between the groups were considered significant if p-values were less than 0.05. All of the variables with
a p-value less than 0.1 in the univariate tests were selected for
a forward stepwise logistic regression.
Crude and adjusted odds ratios were evaluated using
multivariable logistic regression.
The covariates included into the initial analysis were age,
sex, length of intensive care unit stay, mechanical ventilator
use, comorbidities (gastroesophageal reflux disease [GERD],
diabetes mellitus, congestive heart failure, chronic obstructive pulmonary disease [COPD], cerebrovascular disease and
asthma), acute physiology and chronic health evaluation II
(APACHE II) scores, status of tobacco use and medications.
The International Classification of Diseases, Ninth Revision,
Clinical Modification code (ICD-9 CM code) was used to
identify the comorbidities in the electronic medical records.
These were GERD (530.81), diabetes mellitus (250), asthma
(493), heart failure (428), cerebrovascular disease (433, 434),
and COPD (496). The medications included as covariates in
the analysis were benzodiazepines, barbiturates, antipsychotics, opiates, neuromuscular blocking agents, nonsteroid
anti-inflammatory drugs, systemic steroids (cortisone acetate,
hydrocortisone, prednisolone, methylprednisolone, dexamethasone), and anticoagulant agents (enoxaparin, heparin,
warfarin). Propensity score (PS) analysis was conducted
to account for nonrandom treatment allocation by using all
covariates to estimate a score for each patient(21). The final
multivariable regression model included a total of 11 covariates, including the PS, age, sex, ICU stays, APACHE II score,
length of mechanical ventilator use, comorbidities of GERD,
diabetes mellitus, congestive heart failure, COPD and the use
of corticosteroids.
The optimal cutoff points of ICU stay and APACHE II
score were determined by the receiver operating characteristic
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(ROC) curves and Youden’s index.
The effects of dose on the risk of pneumonia were also
evaluated by the defined daily dose (DDD) established by the
World Health Organization. DDD is defined as the assumed
average daily maintenance dose given for the main indication of a drug(22). The patients were therefore categorized
into three groups according to the DDD defined: ≤ 1, 1.1-1.9,
and ≥ 2. All statistical analyses in this study were performed
using the Statistical Package for the Social Science 12.0 Software (SPSS, Inc., Chicago, IL, USA), except the sample size
calculation by the Statistical Package for the Power analysis
and Sample Size 11.0 Software (PASS 11. NCSS, LLC.
Kaysville, Utah, USA).

RESULTS
At first, 1,158 patients admitted into the ICU were identified for possible inclusion in this study. Of these, 770 were
deemed ineligible. The final cohort comprised 388 patients,
of whom 302 patients received PPIs and 86 patients sucralfate
(Figure 1). Table 1 shows the demographic and clinical characteristics of the participants. The percentages of patients on
PPI and sucralfate before ICU admission within the hospital
were not significantly different between the two groups. The
patients on PPI therapy were significantly older than those
who were treated with sucralfate (mean age 71.83 ± 13.02 vs.
68.17 ± 15.46, p = 0.047). They also had a significantly higher
incidence of cerebrovascular disease (22.18% vs. 5.81%, p =
0.001) and a significantly higher APACHE II score (16.92
± 6.96 vs. 15.27 ± 6.11, p = 0.047) than the corresponding
group on sucralfate therapy. In contrast, patients on PPI
therapy showed a significantly shorter length of mechanical
ventilation than the sucralfate group (4.92 ± 8.15 days vs.
8.60 ± 11.57 days, p = 0.007). They also had shorter ICU
stays (9.61 ± 7.47 days vs. 12.63 ± 10.36 days, p = 0.013).
Table 1 summarizes the significant differences observed

Patients who were admitted to ICU and received PPIs or
sucralfate from January 1, 2000 to December 31, 2009
(n = 1158)
Excluded:
1. ICU stay < 2 days (n = 101)
2. Cross over with H2-receptor antagonists (n = 61)
3. A diagnosis of pneumonia within the preceding 3 months (n = 501)
4. A history of clinically significant dysphagia (n = 1)
5. Documented aspiration before ICU admission (n = 42)
6. A history of immunosuppression:
a. Chronic steroid treatment (n = 5)
b. Receipt of chemotherapy within the previous year (n = 57)
c. Treatment with any anti-rejection medication (n = 2)
Patients included in the study
(n = 388)
PPI group
(n = 302)

Figure 1. Study flow chart.

Sucralfate group
(n = 86)

in baseline characteristics between the two groups.
HAP developed in 63 out of 302 patients (20.86%) in the
PPI group and 8 out of 86 patients (9.30%) in the sucralfate
group (unadjusted OR 2.57, 95% CI 1.18-5.60). The area of
ROC was 0.769, indicating acceptable predictability of the
logistic regressions for estimating PS. After adjusting to PS
and other variables, the odds ratio of HAP was 3.37 (95% CI,
1.35-8.45) (Table 2).
Two factors were also associated with the occurrence
of HAP in the multivariable-adjusted logistic regression
model. These were the length of intensive care unit stay (OR
1.09, 95% CI 1.02-1.16) and APACHE II scores (OR 1.07,
95% CI 1.02-1.13). The optimal cutoff points, determined
by analyzing the area under ROC curve and using Youden’s
index, were ≤ 8 days for ICU stays, and ≤ 13 for an APACHE
II score.
Based on these scores, the patients were further categorized into two groups of lower and higher risk. Patients in
the sucralfate group with ICU stays ≤ 8 days served as the
reference group. Patients in the PPI group with ICU stays > 8
Table 1. Characteristics of the Study Population
Variable

PPI
N = 302

Sucralfate
N = 86

Age, mean (range), y

71.83 ± 13.02 68.17 ± 15.46
0.047*
(18-95)
(20-89)

Male, No. (%)

170 (56.29)

39 (45.35)

p Value

0.073

Comorbidities, No. (%)
GERD

12 (3.97)

1 (1.16)

0.348

Diabetes mellitus

138 (45.70)

40 (46.51)

0.893

Congestive heart failure

115 (38.1)

28 (32.6)

0.349

COPD

40 (13.2)

7 (8.1)

0.200

Cerebrovascular disease

67 (22.18)

5 (5.81)

0.001*

Asthma

12 (4.0)

3 (3.5)

0.837

History of tobacco use

106 (35.1)

29 (37.2)

0.813

Mechanical ventilation, d

4.92 ± 8.15

8.60 ± 11.57

0.007*

ICU stay, mean (range), d

9.61 ± 7.47
(3-45)

12.63 ± 10.36
0.013*
(3-54)

APACHE II score

16.92 ± 6.96

15.27 ± 6.11

Previous PPI, No. (%)

15 (4.97)

0.047*

1 (1.63)

0.118

Previous sucralfate, No. (%) 5 (1.66)

3 (3.49)

0.291

DDD, mean ± SD

1.63 ± 0.51

0.302

1.71 ± 1.13

In-ICU medications, No. (%)
Sedative

72 (23.84)

29 (33.72)

0.065

NSAID

78 (25.83)

27 (31.40)

0.504

Anticoagulant

80 (26.49)

16 (18.60)

0.135

Systemic steroid

78 (25.83)

27 (31.40)

0.305

Abbreviations: GERD, gastroesophageal reflux disease; COPD,
chronic obstructive pulmonary disease; DDD, defined daily dose;
NSAID, nonsteroidal anti-inflammatory drug.
A Chi-square test was used to compare categorical variables and an
independent t test for continuous variables. *p < 0.05
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Table 2. Rates of Hospital-Acquired Pneumonia
n (%)
Outcome

Odds ratio

PPI
Sucralfate
(n = 302) (n = 86)

Unadjusted
(95% CI)

Adjusted*
(95% CI)

2.57**
3.37**
(1.18-5.60) (1.35-8.45)

Hospital-acquired
63 (20.86) 8 (9.30)
pneumonia

Abbreviations: CI, confidence interval.
*Regression adjustment was used. All variables include propensity
score, sex, age, ICU stay, ventilator days, APACHE II score, chronic
obstructive pulmonary disease, diabetes mellitus, congestive heart
failure, gastroesophageal reflux disease and systemic steroid use.
** p < 0.05

Table 3. The Association between ICU stays, Sucralfate, PPI and
Hospital-Acquired Pneumonia
ICU stays
aOR (95% CI)

Outcome

Sucralfate (n = 86)
PPI (n = 302)

≤ 8 days

> 8 days

1.0
(n = 42)

2.50 (0.43-14.51)
(n = 44)

1.56 (0.33-7.35)
(n = 184)

9.04* (1.94-42.06)
(n = 118)

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval.
Adjusted variables include: sex, age, ventilator days, APACHE II
score, chronic obstructive pulmonary disease, diabetes mellitus, congestive heart failure, gastroesophageal reflux disease, asthma and
systemic steroid use.
* p < 0.05

Table 4. The Association between APACHE II score, Sucralfate, PPI
and Hospital-Acquired Pneumonia
Outcome

Sucralfate (n = 86)
PPI (n = 302)

APACHE II score
aOR (95% CI)
≤ 13

> 13

1.0
(n = 38)

0.73 (0.14-3.77)
(n = 48)

1.19 (0.29-4.86)
(n = 101)

3.70* (1.04-13.10)
(n = 201)

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval.
Adjusted variables include: sex, age, ventilator days, APACHE II
score, chronic obstructive pulmonary disease, diabetes mellitus, congestive heart failure, gastroesophageal reflux disease, asthma and
systemic steroid use.
* p < 0.05

days had the highest risk for HAP (adjusted OR 9.04, 95% CI
1.94-42.06) (Table 3). A similar finding was observed in the
PPI group with APACHE II scores > 13 (adjusted OR 3.70,
95% CI 1.04-13.10) (Table 4).
The sample size was then confirmed under the following
conditions: the R-square of group with other covariates was

Logistic Regression Power Analysis
Numeric Results
Pcnt N
Power

N

X=1

P0

P1

Odds
R
Alpha
Ratio Squared

Beta

0.79832 294 77.800 0.093 0.257 3.370 0.130 0.05000 0.20168

Report Definitions
Power is the probability of rejecting a false null hypothesis. It
should be close to one.
N is the size of the sample drawn from the population.
P0 is the response probability at the mean of X.
P1 is the response probability when X is increased to one
standard deviation above the mean.
Odds Ratio is the odds ratio when P1 is on top. That is, it is
[P1/(1-P1)]/[P0/(1-P0)].
R-Squared is the R2 achieved when X is regressed on the
other independent variables in the regression.
Alpha is the probability of rejecting a true null hypothesis.
Beta is the probability of accepting a false null hypothesis.
Summary Statements
A logistic regression of a binary response variable (Y)
on a binary independent variable (X) with a sample size of
352 observations (of which 22% are in the group X = 0 and
78% are in the group X = 1) achieves 80% power at a 0.05000
significance level to detect a change in Prob(Y = 1) from the
baseline value of 0.093 to 0.240. This change corresponds to
an odds ratio of 3.076.

equal to 0.13, the HAP of P0 (sucralfate) was equal to 0.093,
and HAP of P1 (PPI) was equal to 0.257. The percentage of
PPI in group was equal to 77.8%. The calculated total sample
size, with a defined ratio of study group as 1 : 3, to reach 80%
of power was 294, and the sample size of present study was
388 (Appendix 1).
To evaluate the dose and relationship of PPIs with the
risk of HAP, the patients in the DDD ≤ 1 were defined as the
reference group. The results indicated that patients with higher
DDD did not have increased risk for HAP (Data not shown).

DISCUSSION
The incidence rates of HAP developed in the medical
ICU were compared between patients who received PPI
and patients who received sucralfate. The PPI group was
revealed to have a higher risk of developing HAP than the
sucralfate group. In addition, those patients on PPI therapy
with ICU stays > 8 days or an APACHE II score > 13 had
an even greater risk of developing HAP. To our knowledge,
no comparative study has compared the outcomes of PPI
and sucralfate therapies for patients in ICUs. No statistically
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significant difference in HAP incidence was found in two
previous randomized control studies performed in a pediatric ICU and a surgical ICU setting(23,24). However, the
insignificance likely resulted from a type II error with only
approximately 40 and 70 patients in each group. The impact
of PPI on gastric pH is more significant than that associated
with H2RA and sucralfate, which consequently results in an
increased risk of HAP caused by gastric colonization with
aerobic gram-negative bacilli(25). Therefore, the incidence
rate of HAP was expected to be higher in the PPI group than
that in the sucralfate group.
The controversial findings on the association of HAP
and PPI in the literatures may result from the ambiguities of
acid-suppressive agent induced HAP. Beaulieu et al. demonstrated that no significant difference in the risk of HAP existed
between patients treated with and without PPI(15). However,
the study defined patients as nonexposed to PPIs if they
developed nosocomial pneumonia following the last dosage
or a treatment with PPIs for more than 14 days. A selection
bias could have been introduced by excluding the late-onset
nosocomial pneumonia induced by PPI. In contrast, PPIs
related to increased incidence rates of HAP were demonstrated in two recent population-based cohort studies(16,26).
Herzig and colleagues showed that HAP incidence increased
by 30% in non-ICU patients receiving PPIs(26). In another
study, conducted by Minao et al., PPI was found to be an
independent risk factor associated with increased HAP in
ICU patients(16), which was consistent with our results.
The optimal cutoff points of ICU stays and APACHE
II scores for the development of HAP were also elucidated
in this study. Ventilator-associated pneumonia (VAP) is
considered the most frequent infection in the ICU. However,
as indicated in a previous study, ICU stays were related to
the incidence of VAP(27). To verify the association between
HAP and ICU stays, we further demonstrated that patients on
PPI therapy had a higher risk of developing HAP if their ICU
stays were longer than 8 days (adjusted OR 9.04, 95% CI
1.94-42.06, p-value 0.005). Additionally, a high APACHE II
score was found to be an independent risk factor for HAP. This
was confirmed by previous studies that investigated the risk
factors for developing VAP(28,29). We delineated the optimal
cut-off points for APACHE II scores and HAP. The results
showed that patients receiving PPI, with an APACHE II score
> 13, were at a higher risk of developing HAP (adjusted OR
3.70, 95% CI 1.04-13.10, p-value 0.043).
The results of this study provide new evidence to
strengthen the current practice of stress ulcer prophylaxis.
The American Society of Health-System Pharmacists
(ASHP) recommends that for patients in general, such as
medical, surgical, respiratory, ICU populations who have
respiratory failure or coagulopathies, use H2RA, antacid
(level A), or sucralfate to prevent stress ulcers (level B)
(30)
. ATS states that, if needed, stress bleeding prophylaxis
with either H2RA or sucralfate is acceptable (Level I)(13).
Although limited information exists on the association of
PPIs with an increased risk of Clostridium difficile disease,
the ATS still recommends that PPI should not be used solely

for stress ulcer prophylaxis in an ICU setting(13). According
to the results of this study, sucralfate could be considered as a
favorable option for stress ulcer prophylaxis in ICU patients.
The phenomenon of dose-dependent-HAP was not
observed in the participants. No previous study has attempted
to evidence the relationship between the dose or duration of
PPI use and the risk of HAP. A significant dose-dependent
risk was only observed for CAP in current users of PPIs.
Persons using more than 1 of DDD had a 2.3-fold increased
risk of CAP compared with past use of acid suppressants(7). A
large nested case-control study showed a modest increase in
risk for CAP among current PPI recipients with high dosing.
But at a daily dose of less than 1.5 times of DDD, current PPI
exposure was not associated with an increased risk for CAP(8).
Further studies to confirm the association of longer-term or
high dose of current PPI therapy with HAP are warranted.
This was a retrospective chart review research. The
main limitations of the present study resided in its observational design and lack of control over treatment assignments.
Information was only obtained through review of computerized medical records and some information on adjustable
risk factors was not available. This included enteral feeding,
nasogastric or oral gastric tube insertion, patient semirecumbent position (30-45°), and oral antiseptic use. Additionally,
the study only included patients from one hospital, and the
generalizability of the study results was diminished. The
information on self-use or prescribed PPI and sucralfate from
other hospitals before admission were not available. This
might limit the study to detect dose- or duration- dependentHAP if exists. The sample size of this study was small, and
thus estimated OR might need to be confirmed in the future.
Our results generates a hypothesis and warrants further
prospective randomized clinical trials (RCT) to investigate
the optimum criteria for the administration of stress ulcer
prophylaxis in ICU patients.

CONCLUSIONS
The present study demonstrated that PPI therapy was
associated with a higher risk for HAP in ICU patients than
sucralfate therapy. The risk was higher in patients on PPI
therapy and with an ICU stay > 8 days or with an APACHE
II score > 13. Considering the results obtained by this study
and the current clinical practice guidelines, the use of sucralfate should be a priority for stress ulcer prophylaxis in ICU
patients. For patients with an APACHE II score > 13 or an
expected long ICU stay, the risks and benefits of PPI therapy
should be carefully evaluated.

ACKNOWLEDGMENTS
This study was supported in part by grant no.
CMRPG290141 from Chang Gung Memorial Hospital,
Keelung, Taiwan. The authors bear all responsibility and have
no conflict of interest with regard to this work.

575
Journal of Food and Drug Analysis, Vol. 20, No. 3, 2012

The authors thank all the patients for their contributions
to this research.

References
1. Eom, C. S., Jeon, C. Y. and Lim, J. W. et al. 2011. Use of
acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 183: 310-319.
2. Kollef, M. H. 1999. The prevention of ventilator-associated pneumonia. N. Engl. J. Med. 340: 627-634.
3. Hunter, J. D. 2006. Ventilator associated pneumonia.
Postgrad. Med. J. 82: 172-178.
4. Driks, M. R., Craven, D. E. and Celli, B. R. et al. 1987.
Nosocomial pneumonia in intubated patients given
sucralfate as compared with antacids or histamine type
2 blockers. the role of gastric colonization. N. Engl. J.
Med. 317: 1376-1382.
5. Prod’hom, G., Leuenberger, P. and Koerfer, J. et al.
1994. Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate
as prophylaxis for stress ulcer. A randomized controlled
trial. Ann. Intern. Med. 120: 653-662.
6. Tryba, M. 1987. Risk of acute stress bleeding and nosocomial pneumonia in ventilated intensive care unit patients:
sucralfate versus antacids. Am. J. Med. 83: 117-124.
7. Laheij, R. J., Sturkenboom, M. C. and Hassing, R. J. et al.
2004. Risk of community-acquired pneumonia and use of
gastric acid-suppressive drugs. JAMA 292: 1955-1960.
8. Sarkar, M., Hennessy, S. and Yang, Y. X. 2008. Protonpump inhibitor use and the risk for community-acquired
pneumonia. Ann. Intern. Med. 149: 391-398.
9. Gulmez, S. E., Holm, A., Frederiksen, H., Jensen, T. G.,
Pedersen, C. and Hallas, J. 2007. Use of proton pump
inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch.
Intern. Med. 167: 950-955.
10. Myles, P. R., Hubbard, R. B., McKeever, T. M., Pogson,
Z., Smith, C. J. and Gibson, J. E. 2009. Risk of community-acquired pneumonia and the use of statins, ace
inhibitors and gastric acid suppressants: a populationbased case-control study. Pharmacoepidemiol. Drug Saf.
18: 269-275.
11. Eurich, D. T., Sadowski, C. A., Simpson, S. H., Marrie,
T. J. and Majumdar, S. R. 2010. Recurrent communityacquired pneumonia in patients starting acid-suppressing
drugs. Am. J. Med. 123: 47-53.
12. Fallell, C. P., Mercogliano, G. and Kuntz, C. L. 2010.
Overuse of stress ulcer prophylaxis in the critical care
setting and beyond. J. Crit. Care. 25: 214-220.
13. American Thoracic Society. 2005. Guidelines for the
management of adults with hospital-acquired, ventilatorassociated, and healthcare-associated pneumonia. Am. J.
Respir. Crit. Care Med. 171: 388-416.
14. Dellinger, R. P., Levy, M. M. and Carlet, J. M. et al.
2008. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock:

2008. Intens. Care Med. 34: 17-60.
15. Beaulieu, M., Williamson, D., Sirois, C. and Lachaine,
J. 2008. Do proton-pump inhibitors increase the risk for
nosocomial pneumonia in a medical intensive care unit?
J. Crit. Care. 23: 513-518.
16. Miano, T. A., Reichert, M. G., Houle, T. T., MacGregor,
D. A., Kincaid, E. H. and Bowton, D. L. 2009. Nosocomial pneumonia risk and stress ulcer prophylaxis: a
comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. Chest 136: 440-447.
17. Cook, D. J., Fuller, H. D. and Guyatt, G. H. et al. 1994.
Risk factors for gastrointestinal bleeding in critically ill
patients. N. Engl. J. Med. 330: 377-381.
18. Guillamondegui, O. D., Gunter, O. L. and Ronaides, J.
A. et al. 2008. Practice management guidelines for stress
ulcer prophylaxis. Chicago, Eastern Association for the
Surgery of Trauma (EAST). http://www.guideline.gov/
summary/
19. Cook, D. J., Guyatt, G. and Marshall, J. et al.1998. A
comparison of sucralfate and ranitidine for the prevention
of upper gastrointestinal bleeding in patients requiring
mechanical ventilation. N. Engl. J. Med. 338: 791-797.
20. Kieninger, A. N. and Lipsett, P. A. 2009. Hospitalacquired pneumonia: pathophysiology, diagnosis, and
treatment. Surg. Clin. North Am. 89: 439-461.
21. Dattalo, P. 2009. Statistical alternatives and supplements
to random supplements assignment. In “Strategies to
Approximate Random Sampling and Assignment”. 1st
ed. pp.109-149. Tripodi, T. ed. Oxford University Press.
New York, U.S.A.
22. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD
assignment, 2010. http://www.whocc.no/filearchive/
publications/2010guidelines.pdf
23. Yildizdas, D., Yapicioglu, H. and Yilmaz, H. L. 2002.
Occurrence of ventilator-associated pneumonia in
mechanically ventilated pediatric intensive care patients
during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. J. Crit. Care 17: 240-245.
24. Kantorova, I., Svoboda, P. and Scheer, P. et al. 2004.
Stress ulcer prophylaxis in critically ill patients: a
randomized controlled trial. Hepatogastroenterology 51:
757-761.
25. Eddleston, J. M., Vohra, A. and Scott, P. et al. 1991.
A comparison of the frequency of stress ulceration
and secondary pneumonia in sucralfate- or ranitidinetreated intensive care unit patients. Crit. Care Med. 19:
1491-1496.
26. Herzig, S. J., Howell, M. D., Ngo, L. H. and Marcantonio, E. R. 2009. Acid-suppressive medication use and
the risk for hospital-acquired pneumonia. JAMA 301:
2120-2128.
27. Wu, S. C. and Chen, C. C. 2004. Study on factors for
ventilator-associated pneumonia in intensive care unit.
Taiwan J. Public Health 23: 440-446.
28. Apostolopoulou, E., Bakakos, P., Katostaras, T. and
Gregorakos, L. 2003. Incidence and risk factors for

576
Journal of Food and Drug Analysis, Vol. 20, No. 3, 2012

ventilator-associated pneumonia in 4 multidisciplinary
intensive care units in Athens, Greece. Respir. Care 48:
681-688.
29. Gacouin, A., Barbarot, N. and Camus, C. et al. 2009.
Late-onset ventilator-associated pneumonia in
nontrauma intensive care unit patients. Anesth. Analg.
109: 1584-1590.

30. ASHP Commission on Therapeutics. 1999. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. Am. J.
Health Syst. Pharm. 56: 347-379.

